{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:07:27Z","timestamp":1785150447836,"version":"3.55.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06883"],"award-info":[{"award-number":["21K06883"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation,Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kurozumi Medical Foundation,Japan"},{"name":"National Institutes of Health,United States","award":["P01 CA229100"],"award-info":[{"award-number":["P01 CA229100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11899-023-00712-9","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:02:12Z","timestamp":1698051732000},"page":"252-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders"],"prefix":"10.1007","volume":"18","author":[{"given":"Naoki","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"712_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"\u2022\u2022 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. The most recent version of the World Health Organization (WHO) classification.","journal-title":"Leukemia"},{"key":"712_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"\u2022\u2022 Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353. The 2022 International Consensus Classification (ICC) by the Clinical Advisory Committee.","journal-title":"Blood"},{"key":"712_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.path.2023.01.011","volume":"16","author":"N Oishi","year":"2023","unstructured":"Oishi N, Feldman AL. Current concepts in nodal peripheral T-cell lymphomas. Surg Pathol Clin. 2023;16:267\u201385.","journal-title":"Surg Pathol Clin"},{"key":"712_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00428-022-03412-6","volume":"482","author":"AL Feldman","year":"2023","unstructured":"Feldman AL, Laurent C, Narbaitz M, et al. Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas. Virchows Arch. 2023;482:265\u201379.","journal-title":"Virchows Arch"},{"key":"712_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00428-022-03434-0","volume":"482","author":"L de Leval","year":"2023","unstructured":"de Leval L, Feldman AL, Pileri S, et al. Extranodal T- and NK-cell lymphomas. Virchows Arch. 2023;482:245\u201364.","journal-title":"Virchows Arch"},{"key":"712_CR6","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"712_CR7","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood.2022015854","volume":"140","author":"L de Leval","year":"2022","unstructured":"de Leval L, Alizadeh AA, Bergsagel PL, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022;140:2193\u2013227.","journal-title":"Blood"},{"key":"712_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2019000402","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134:1132\u201343.","journal-title":"Blood"},{"key":"712_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/gcc.22821","volume":"59","author":"P Patil","year":"2020","unstructured":"Patil P, Cieslak A, Bernhart SH, et al. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. Genes Chromosom Cancer. 2020;59:261\u20137.","journal-title":"Genes Chromosom Cancer"},{"key":"712_CR10","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HLM Koskela","year":"2012","unstructured":"Koskela HLM, Eldfors S, Ellonen P, et al. Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia. N Engl J Med. 2012;366:1905\u201313.","journal-title":"N Engl J Med"},{"key":"712_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.humpath.2017.12.014","volume":"73","author":"M Shi","year":"2018","unstructured":"Shi M, He R, Feldman AL, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74\u201381.","journal-title":"Hum Pathol"},{"key":"712_CR12","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","volume":"121","author":"HLM Rajala","year":"2013","unstructured":"Rajala HLM, Eldfors S, Kuusanm\u00e4ki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121:4541\u201350.","journal-title":"Blood"},{"key":"712_CR13","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood-2016-06-724856","volume":"128","author":"EI Andersson","year":"2016","unstructured":"Andersson EI, Tanahashi T, Sekiguchi N, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128:2465\u20138.","journal-title":"Blood"},{"key":"712_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1111\/cas.14869","volume":"112","author":"K Nosaka","year":"2021","unstructured":"Nosaka K, Matsuoka M. Adult T-cell leukemia-lymphoma as a viral disease: Subtypes based on viral aspects. Cancer Sci. 2021;112:1688\u201394.","journal-title":"Cancer Sci"},{"key":"712_CR15","first-page":"198","volume":"5","author":"K Karube","year":"2021","unstructured":"Karube K, Takatori M, Sakihama S, et al. Clinicopathological features of adult T-cell leukemia\/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Blood Adv. 2021;5:198\u2013206.","journal-title":"Blood Adv"},{"key":"712_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100169","volume":"36","author":"T Tamaki","year":"2023","unstructured":"Tamaki T, Karube K, Sakihama S, et al. a comprehensive study of the immunophenotype and its clinicopathologic significance in adult T-cell leukemia\/lymphoma. Mod Pathol. 2023;36: 100169.","journal-title":"Mod Pathol"},{"key":"712_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/modpathol.2008.25","volume":"21","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Sugita Y, et al. The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia\/lymphoma. Mod Pathol. 2008;21:617\u201325.","journal-title":"Mod Pathol"},{"key":"712_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41379-020-0635-8","volume":"34","author":"M Takatori","year":"2021","unstructured":"Takatori M, Sakihama S, Miyara M, et al. A new diagnostic algorithm using biopsy specimens in adult T-cell leukemia\/lymphoma: combination of RNA in situ hybridization and quantitative PCR for HTLV-1. Mod Pathol. 2021;34:51\u20138.","journal-title":"Mod Pathol"},{"key":"712_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41379-020-00654-0","volume":"34","author":"K Yamada","year":"2021","unstructured":"Yamada K, Miyoshi H, Yoshida N, et al. Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia\/lymphoma. Mod Pathol. 2021;34:314\u201326.","journal-title":"Mod Pathol"},{"key":"712_CR20","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/cas.13303","volume":"108","author":"Y Kogure","year":"2017","unstructured":"Kogure Y, Kataoka K. Genetic alterations in adult T-cell leukemia\/lymphoma. Cancer Sci. 2017;108:1719\u201325.","journal-title":"Cancer Sci"},{"key":"712_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood.2021013568","volume":"139","author":"Y Kogure","year":"2022","unstructured":"\u2022 Kogure Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia\/lymphoma. Blood. 2022;139:967\u201382. A comprehensive molecular study of adult T-cell luekemia\/lymphoma (ATLL).","journal-title":"Blood"},{"key":"712_CR22","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"712_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature. 2016;534:402\u20136.","journal-title":"Nature"},{"key":"712_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1084\/jem.20160894","volume":"214","author":"AB Moffitt","year":"2017","unstructured":"Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371\u201386.","journal-title":"J Exp Med"},{"key":"712_CR25","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1182\/blood-2018-01-830968","volume":"131","author":"A Sharma","year":"2018","unstructured":"Sharma A, Oishi N, Boddicker RL, et al. Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood. 2018;131:2262\u20136.","journal-title":"Blood"},{"key":"712_CR26","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","volume":"122","author":"AM Perry","year":"2013","unstructured":"Perry AM, Warnke AR, Hu Q, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122:3599\u2013606.","journal-title":"Blood"},{"key":"712_CR27","doi-asserted-by":"publisher","first-page":"e68343","DOI":"10.1371\/journal.pone.0068343","volume":"8","author":"E Margolskee","year":"2013","unstructured":"Margolskee E, Jobanputra V, Lewis SK, et al. Indolent Small Intestinal CD4+ T-cell Lymphoma Is a Distinct Entity with Unique Biologic and Clinical Features. Tran DQ, ed. PLoS One. 2013;8:e68343.","journal-title":"PLoS One"},{"key":"712_CR28","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3324\/haematol.2019.230961","volume":"105","author":"CR Soderquist","year":"2020","unstructured":"Soderquist CR, Patel N, Murty VV, et al. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica. 2020;105:1895\u2013906.","journal-title":"Haematologica"},{"key":"712_CR29","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1182\/blood-2010-06-290650","volume":"116","author":"K Takeuchi","year":"2010","unstructured":"Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: A distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 2010;116:5631\u20137.","journal-title":"Blood"},{"key":"712_CR30","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1182\/blood-2010-08-302737","volume":"117","author":"A Mansoor","year":"2011","unstructured":"Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 2011;117:1447\u201352.","journal-title":"Blood"},{"key":"712_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood.2019001443","volume":"134","author":"W Xiao","year":"2019","unstructured":"Xiao W, Gupta GK, Yao J, et al. Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 2019;134:986\u201391.","journal-title":"Blood"},{"key":"712_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.humpath.2018.01.005","volume":"74","author":"M Yabe","year":"2018","unstructured":"Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. Hum Pathol. 2018;74:5\u201316.","journal-title":"Hum Pathol"},{"key":"712_CR33","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/leu.2014.200","volume":"28","author":"A Nicolae","year":"2014","unstructured":"Nicolae A, Xi L, Pittaluga S, et al. Frequent STAT5B mutations in \u03b3\u03b4 hepatosplenic T-cell lymphomas. Leukemia. 2014;28:2244\u20138.","journal-title":"Leukemia"},{"key":"712_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","volume":"7","author":"M McKinney","year":"2017","unstructured":"McKinney M, Moffitt AB, Gaulard P, et al. The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov. 2017;7:369\u201379.","journal-title":"Cancer Discov"},{"key":"712_CR35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/PAS.0000000000001941","volume":"46","author":"AL Feldman","year":"2022","unstructured":"Feldman AL, Oishi N, Ketterling RP, et al. Immunohistochemical approach to genetic subtyping of anaplastic large cell lymphoma. Am J Surg Pathol. 2022;46:1490\u20139.","journal-title":"Am J Surg Pathol"},{"key":"712_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/PAS.0000000000001614","volume":"45","author":"A Ravindran","year":"2021","unstructured":"Ravindran A, Feldman AL, Ketterling RP, et al. Striking association of lymphoid enhancing factor (LEF1) overexpression and DUSP22 rearrangements in anaplastic large cell lymphoma. Am J Surg Pathol. 2021;45:550\u20137.","journal-title":"Am J Surg Pathol"},{"key":"712_CR37","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","volume":"117","author":"AL Feldman","year":"2011","unstructured":"Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117:915\u20139.","journal-title":"Blood"},{"key":"712_CR38","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood.2019000626","volume":"133","author":"RA Luchtel","year":"2019","unstructured":"Luchtel RA, Zimmermann MT, Hu G, et al. Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. Blood. 2019;133:2776\u201389.","journal-title":"Blood"},{"key":"712_CR39","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","volume":"132","author":"RA Luchtel","year":"2018","unstructured":"Luchtel RA, Dasari S, Oishi N, et al. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood. 2018;132:1386\u201398.","journal-title":"Blood"},{"key":"712_CR40","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","volume":"120","author":"G Vasmatzis","year":"2012","unstructured":"Vasmatzis G, Johnson SH, Knudson AR, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120:2280\u20139.","journal-title":"Blood"},{"key":"712_CR41","first-page":"700","volume":"135","author":"K Karube","year":"2020","unstructured":"Karube K, Feldman AL. \u201cDouble-hit\u201d of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma. ALK-negative Blood. 2020;135:700\u2013700.","journal-title":"ALK-negative Blood"},{"key":"712_CR42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27:516\u201332.","journal-title":"Cancer Cell"},{"key":"712_CR43","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/PAS.0000000000001708","volume":"45","author":"MJ Fitzpatrick","year":"2021","unstructured":"Fitzpatrick MJ, Massoth LR, Marcus C, et al. JAK2 rearrangements are a recurrent alteration in CD30+ systemic T-cell lymphomas with anaplastic morphology. Am J Surg Pathol. 2021;45:895\u2013904.","journal-title":"Am J Surg Pathol"},{"key":"712_CR44","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/leu.2017.309","volume":"32","author":"G Hu","year":"2018","unstructured":"Hu G, Dasari S, Asmann YW, et al. Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia. 2018;32:565\u20139.","journal-title":"Leukemia"},{"key":"712_CR45","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parilla Castellar","year":"2014","unstructured":"Parilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473\u201380.","journal-title":"Blood"},{"key":"712_CR46","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","volume":"130","author":"MB Pedersen","year":"2017","unstructured":"Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130:554\u20137.","journal-title":"Blood"},{"key":"712_CR47","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.3324\/haematol.2018.205880","volume":"104","author":"A Onaindia","year":"2019","unstructured":"Onaindia A, de Villambros\u00eda SG, Prieto-Torres L, et al. DUSP22 -rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK\/STAT surrogate markers. Haematologica. 2019;104:e158\u201362.","journal-title":"Haematologica"},{"key":"712_CR48","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/bjh.15860","volume":"186","author":"G Hapgood","year":"2019","unstructured":"Hapgood G, Ben-Neriah S, Mottok A, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186:e28\u201331.","journal-title":"Br J Haematol"},{"key":"712_CR49","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2022.281222","volume":"108","author":"L Qiu","year":"2022","unstructured":"Qiu L, Tang G, Li S, et al. DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 2022;108:1604\u201315.","journal-title":"Haematologica"},{"key":"712_CR50","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","volume":"132","author":"N Oishi","year":"2018","unstructured":"Oishi N, Brody GS, Ketterling RP, et al. Genetic subtyping of breast implant\u2013associated anaplastic large cell lymphoma. Blood. 2018;132:544\u20137.","journal-title":"Blood"},{"key":"712_CR51","first-page":"360","volume":"135","author":"C Laurent","year":"2020","unstructured":"\u2022 Laurent C, Nicolae A, Laurent C, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. Blood. 2020;135:360\u201370. An extensive study on the genetics of breast implant-associated ALCL.","journal-title":"Blood"},{"key":"712_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/tbj.14205","volume":"27","author":"AE Quesada","year":"2021","unstructured":"Quesada AE, Zhang Y, Ptashkin R, et al. Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway. Breast J. 2021;27:314\u201321.","journal-title":"Breast J"},{"key":"712_CR53","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3324\/haematol.2019.245860","volume":"106","author":"N Oishi","year":"2020","unstructured":"Oishi N, Hundal T, Phillips JL, et al. Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica. 2020;106:1714\u201324.","journal-title":"Haematologica"},{"key":"712_CR54","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/his.14666","volume":"81","author":"N Oishi","year":"2022","unstructured":"Oishi N, Feldman AL. CA9 expression in breast implant-associated anaplastic large cell lymphoma presenting in a lymph node. Histopathology. 2022;81:270\u20132.","journal-title":"Histopathology"},{"key":"712_CR55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171\u20135.","journal-title":"Nat Genet"},{"key":"712_CR56","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al. Activation of RHOA\u2013VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018;32:694\u2013702.","journal-title":"Leukemia"},{"key":"712_CR57","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166\u201370.","journal-title":"Nat Genet"},{"key":"712_CR58","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.leu.2404045","volume":"20","author":"B Streubel","year":"2006","unstructured":"Streubel B, Vinatzer U, Willheim M, et al. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20:313\u20138.","journal-title":"Leukemia"},{"key":"712_CR59","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","volume":"33","author":"Y Huang","year":"2009","unstructured":"Huang Y, Moreau A, Dupuis J, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol. 2009;33:682\u201390.","journal-title":"Am J Surg Pathol"},{"key":"712_CR60","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1097\/PAS.0000000000001315","volume":"43","author":"BM Basha","year":"2019","unstructured":"Basha BM, Bryant SC, Rech KL, et al. Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with t-follicular helper phenotype. Am J Surg Pathol. 2019;43:1282\u201390.","journal-title":"Am J Surg Pathol"},{"key":"712_CR61","first-page":"2194","volume":"141","author":"J Ruan","year":"2023","unstructured":"Ruan J, Moskowitz AJ, Mehta-Shah N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma. Blood. 2023;141:2194\u2013205.","journal-title":"Blood"},{"key":"712_CR62","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4:4640\u20137.","journal-title":"Blood Adv"},{"key":"712_CR63","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137:2161\u201370.","journal-title":"Blood"},{"key":"712_CR64","doi-asserted-by":"crossref","unstructured":"Drieux F, Ruminy P, Abdel-Sater A, Lemonnier F, Viailly PJ, Fataccioli V, et al. Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay. Haematologica. 2020;105(6):1582\u201392.","DOI":"10.3324\/haematol.2019.226647"},{"key":"712_CR65","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133:1664\u201376.","journal-title":"Blood"},{"key":"712_CR66","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","volume":"123","author":"T Wang","year":"2014","unstructured":"Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123:3007\u201315.","journal-title":"Blood"},{"key":"712_CR67","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood.2019000779","volume":"134","author":"C Amador","year":"2019","unstructured":"Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood. 2019;134:2159\u201370.","journal-title":"Blood"},{"key":"712_CR68","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood.2021015019","volume":"140","author":"TA Herek","year":"2022","unstructured":"\u2022 Herek TA, Bouska A, Lone W, et al. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood. 2022;140:1278\u201390. A study showing the distinct molecular profile of peripheral T-cell lymphoma (PTCL) of cytotoxic phenotype.","journal-title":"Blood"},{"key":"712_CR69","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41379-022-01022-w","volume":"35","author":"A Nicolae","year":"2022","unstructured":"Nicolae A, Bouilly J, Lara D, et al. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. Mod Pathol. 2022;35:1126\u201336.","journal-title":"Mod Pathol"},{"key":"712_CR70","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/PAS.0b013e31824433d8","volume":"36","author":"T Pongpruttipan","year":"2012","unstructured":"Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK\/T-cell lymphoma, nasal type, includes cases of natural killer cell and \u03b1\u03b2, \u03b3\u03b4, and \u03b1\u03b2\/\u03b3\u03b4 T-cell origin. Am J Surg Pathol. 2012;36:481\u201399.","journal-title":"Am J Surg Pathol"},{"key":"712_CR71","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PAS.0000000000000323","volume":"39","author":"S Kato","year":"2015","unstructured":"Kato S, Asano N, Miyata-Takata T, et al. T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases. Am J Surg Pathol. 2015;39:462\u201371.","journal-title":"Am J Surg Pathol"},{"key":"712_CR72","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/modpathol.2016.47","volume":"29","author":"M Hong","year":"2016","unstructured":"Hong M, Lee T, Young Kang S, et al. Nasal-type NK\/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA and protein studies: lineage does not predict clinical behavior. Mod Pathol. 2016;29:430\u201343.","journal-title":"Mod Pathol"},{"key":"712_CR73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/bloodadvances.2022007541","volume":"7","author":"N Oishi","year":"2023","unstructured":"Oishi N, Satou A, Miyaoka M, et al. Genetic and immunohistochemical profiling of NK\/T-cell lymphomas reveals prognostically relevant BCOR -MYC association. Blood Adv. 2023;7:178\u201389.","journal-title":"Blood Adv"},{"key":"712_CR74","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41379-019-0415-5","volume":"33","author":"IA Montes-Mojarro","year":"2020","unstructured":"Montes-Mojarro IA, Chen B-J, Ramirez-Ibarguen AF, et al. Mutational profile and EBV strains of extranodal NK\/T-cell lymphoma, nasal type in Latin America. Mod Pathol. 2020;33:781\u201391.","journal-title":"Mod Pathol"},{"key":"712_CR75","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu Z-H, Yan Z-X, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47:1061\u20136.","journal-title":"Nat Genet"},{"key":"712_CR76","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/s41375-022-01623-z","volume":"36","author":"G Dong","year":"2022","unstructured":"\u2022 Dong G, Liu X, Wang L, et al. Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer\/T-cell lymphoma. Leukemia. 2022;36:2064\u201375. A molecular study demonstrating genetic heterogeneity of extranodal NK\/T-cell lymphoma.","journal-title":"Leukemia"},{"key":"712_CR77","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui B-W, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020;37:403-419.e6.","journal-title":"Cancer Cell"},{"key":"712_CR78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00428-022-03414-4","volume":"482","author":"L Quintanilla-Martinez","year":"2023","unstructured":"Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, et al. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. 2023;482:227\u201344.","journal-title":"Virchows Arch"},{"key":"712_CR79","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3960\/jslrt.20001","volume":"60","author":"S Kato","year":"2020","unstructured":"Kato S, Yamashita D, Nakamura S. Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification. J Clin Exp Hematop. 2020;60:30\u20136.","journal-title":"J Clin Exp Hematop"},{"key":"712_CR80","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3324\/haematol.2017.180430","volume":"103","author":"S-B Ng","year":"2018","unstructured":"Ng S-B, Chung T-H, Kato S, et al. Epstein-Barr virus-associated primary nodal T\/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2018;103:278\u201387.","journal-title":"Haematologica"},{"key":"712_CR81","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","volume":"107","author":"CMM Wai","year":"2022","unstructured":"Wai CMM, Chen S, Phyu T, et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022;107:1864\u201379.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00712-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T10:19:08Z","timestamp":1702030748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00712-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00712-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"7 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoki Oishi and Reham Ahmed declare that they have no conflict of interest. Andrew L. Feldman has received research funding from Seattle Genetics and is an inventor of technology discussed in this article for which Mayo Clinic holds an unlicensed patent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}